Global Trac Solutions, Inc. CEO, David Flores, sits down with Kelli Foulkrod.
Similar Posts
Psychedelic stocks: the next BILLION dollar industry (2 mushroom stocks you MUST own in 2020)
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
![Compass Pathways Q4 Earnings Call Highlights [Is CMPS Closing In On MindMed?]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-47-600x338.jpeg)
Compass Pathways Q4 Earnings Call Highlights [Is CMPS Closing In On MindMed?]
Hey guys! I promised ya’ll that I will keep you updated on Compass Pathways (NASDAQ: CMPS) earnings call. There has been some pretty interesting developments on the company that I thought I should Bring to your attention. Compass Pathways is one of the psychedelic companies that is the furthest advanced in their clinical trials (Phase IIB to treat TRD). However, I wasn’t aware that they are doing a LOT more. This is quite interesting because in my opinion, CMPS is not a one trick pony anymore and it might as well be in direct competition with my favorite company in this sector (MindMed).
In this video, we’ll cover:
1. Compass Pathways’ Financials
2. Their IP
3. Therapists Training
4. Future Projects
5. Digital Technology
I hope that this is not going to enrage the MindMed fan boys out there. I just thought that it might be interesting for some of you psychedelic investors.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-Depressive
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#CompassPathways #CMPS #MindMed
Interview With David Dardashti, Founder of Ibogaine clinic
David Dardashti talks about his Ibogaine clinic in Mexico, where he’s treated more than 8,500 people from trauma, addiction, and health issues.
Removing Barriers of Accessibility to Psychedelics with Brett Waters
Brett also introduces the collaborative efforts of Reason for Hope’s team, which includes strategic minds from various fields, working together in drafting legislation, preparing legal briefings, educating legislators, and building advocacy coalitions. Currently, Reason for Hope focuses on establishing MDMA- and psilocybin-assisted therapy expanded access pilot programs for those unable to wait for FDA approval.
MindCure CEO Kelsey Ramsden – The Psychedelic Space Is Unlike Any Other Drug Development Sector
In this interview with Kelsey Ramsden, CEO on MindCure Health…
The Psychedelic CEO Round Table | feat. MindMed, Cybin, Field Trip and the Psychedelic Investor
The Psychedelic CEO Round Table | feat. MindMed, Cybin, Field Trip and the Psychedelic Investor
Join the Psychedelic Investor and the CEOs of MindMed (Rob Barrow) and Cybin (Doug Drysdale), and the Executive Chairman of Field Trip (Ronan Levy) as they discuss the future of psychedelic medicines.
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
If you are interested in investing in psychedelic stocks, then this is the even for you. Full of knowledge and unique information, this CEO discussion is a must.
Learn about the companies behind MindMed’s stock (Nasdaq: MNMD, NEO: MMED), Cybin’s stock (NYSE: CYBN, NEO: CYBN) and Field Trip Health’s stock (Nasdaq: FTRP, TSX: FTRP).
Presented by PsychedelicSpotlight.com, this conversation is as great a starting place as any to learn about psychedelic stocks
#Psychedelics #MindMed #Investing